Serina Therapeutics, Inc. Overview
Pro stress-test →Serina Therapeutics is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The company focuses on advancing its POZ platform technology with a lead program in Parkinson's disease treatment.
Strategic Profile
Pro stress-test →The POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). The company is developing its lead candidate SER-252 for advanced Parkinson's disease in a Phase 1b registrational trial aligned with an FDA 505(b)(2) NDA pathway.
Competitive Landscape
Pro stress-test →Serina competes in the neurological disease space against larger pharmaceutical companies and biotechs developing Parkinson's treatments. Its POZ platform differentiates it through novel drug delivery capabilities, though the company faces resource constraints compared to well-capitalized competitors. The clinical-stage status limits competitive positioning until Phase 1b trial results are achieved.
Industry Context
Serina Therapeutics, Inc. operates in Biotechnology - Neurological Therapeutics.
Key facts
Founded: 2006 · Headquarters: Huntsville, Alabama · Market cap: $18.87M